Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
29.50
+0.19 (+0.65%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pfizer
< Previous
1
2
...
29
30
31
32
33
34
35
36
37
...
99
100
Next >
ROSEN, A RANKED AND LEADING FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 23, 2024
WHY: NEW YORK, NY - (NewMediaWire) - January 23, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Maximizing Tax Deductions: 3 Charity-Friendly Stocks to Consider
January 23, 2024
Pick charity-friendly stocks for a balanced approach to ethical investing. It's a perfect mix of financial wisdom and social responsibility.
Via
InvestorPlace
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
January 23, 2024
Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.
Via
Benzinga
How To Earn $500 Per Month From Pfizer Stock
January 23, 2024
Via
Benzinga
Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup
January 23, 2024
Bristol Myer's Opdivo/Yervoy's long-term survival benefits in CheckMate-214 trial for advanced renal cell carcinoma. Significant reductions in risk of death, improved OS, PFS, and ORR after eight...
Via
Benzinga
Competitor Analysis: Evaluating Pfizer And Competitors In Pharmaceuticals Industry
January 22, 2024
Via
Benzinga
Wednesday Is Your Last Chance To Buy Pfizer Before The Dividend Payout
January 22, 2024
Via
Benzinga
Is Lilly Getting Silly?
January 18, 2024
An old-school drug company, Eli Lilly (LLY), has worked its way into the
Via
Talk Markets
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
January 23, 2024
Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases.
Via
MarketBeat
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 22, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
3 Ultra-High-Yield Dividend Stocks That Are Simply Too Cheap to Ignore
January 22, 2024
These stocks check off all the boxes for income and value investors.
Via
The Motley Fool
2 Incredible Growth Stocks That Are Screaming Buys for 2024
January 22, 2024
These healthcare businesses are compelling buys for very different reasons.
Via
The Motley Fool
Check Out What Whales Are Doing With PFE
January 18, 2024
Via
Benzinga
Why Pfizer Stock Is a Fantastic Pharma Comeback Candidate
January 17, 2024
If Pfizer can seize a piece of the obesity-drug pie, PFE stock has the potential to rebound sharply this year.
Via
InvestorPlace
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 21, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 20, 2024
WHY: NEW YORK, NY - (NewMediaWire) - January 20, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of...
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
4 Magnificent Stocks I'm Done Waiting on a Dip for in 2024 -- but I'm Not Buying Them Hand Over Fist, Either
January 20, 2024
These stocks never seem to go on sale. Here's why I'm buying them anyway.
Via
The Motley Fool
Better Bull Market Buy: Pfizer vs. Moderna
January 20, 2024
There could be a light at the end of the COVID-19 tunnel for both of these beaten-down stocks.
Via
The Motley Fool
Exposures
COVID-19
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 19, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Ex-Pfizer Employee Netted $270,000 In Illicit Profits Tied To Paxlovid Results
January 19, 2024
A jury found the former senior statistical lead guilty of securities fraud and conspiracy to commit securities fraud.
Via
Investor's Business Daily
Topics
Fraud
Exposures
Legal
Pfizer, Autodesk, AbbVie And More: CNBC's 'Final Trades'
January 19, 2024
On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named Health Care Select Sector SPDR Fund (NYSE: XLV)
Via
Benzinga
Pfizer Insider Trading: Former Employee Found Guilty Of Trading On Successful COVID-19 Paxlovid Trial News
January 19, 2024
Amit Dagar, ex-Pfizer lead, guilty of securities fraud for insider trading on COVID drug trial info.
Via
Benzinga
Topics
Fraud
Exposures
COVID-19
Legal
3 No-Brainer Stocks to Buy Right Now for Less than $50
January 19, 2024
A little upfront money can go a long way with these three stocks.
Via
The Motley Fool
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 18, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
3 Pharma Stocks Could Be the Pills Your Portfolio Needs
January 18, 2024
These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations.
Via
InvestorPlace
Inflation-Busting Price Hikes For Ozempic, Mounjaro And Others: Are Drugmakers Profiteering?
January 18, 2024
Pharmaceuticals prices are already up in 2024: Can inflation-beating hikes be justified?
Via
Benzinga
Anthropic's Claude Chatbot Gets an Upgrade with Image Analysis, Challenging Google and OpenAI
January 17, 2024
Anthropic's Chatbot Claude Set to Analyze Images, Rivaling Google Bard and ChatGPT. This new feature in Claude could elevate user interaction, offering tasks like image comparison and artwork...
Via
Benzinga
GSK Cuts More Stake In Its Spun-Off Consumer-Healthcare Business Haleon, Raises Over £900M
January 17, 2024
GSK sells 300M shares in Haleon at £326/share, raising £978M. GSK to retain 4.2% stake.
Via
Benzinga
UnitedHealth's rising premiums could cushion stubborn inflation
January 17, 2024
The healthcare sector is one of the prime suspects to attract safety-seeking investors in the coming market shift. Within it, THIS stock can prove a winner
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units
January 16, 2024
On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units.
Via
Benzinga
Topics
ETFs
< Previous
1
2
...
29
30
31
32
33
34
35
36
37
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.